{"id":8884,"date":"2024-08-25T08:19:50","date_gmt":"2024-08-25T08:19:50","guid":{"rendered":"https:\/\/news.godj.com\/news\/promising-lung-cancer-vaccine-trial-starts-in-uk\/"},"modified":"2024-08-25T08:19:50","modified_gmt":"2024-08-25T08:19:50","slug":"promising-lung-cancer-vaccine-trial-starts-in-uk","status":"publish","type":"post","link":"https:\/\/news.godj.com\/news\/promising-lung-cancer-vaccine-trial-starts-in-uk\/","title":{"rendered":"Promising lung cancer vaccine trial starts in UK"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div id=\"\">\n<figure>\n<div data-component=\"image-block\" class=\"sc-18fde0d6-0 ejjhCR\">\n<div data-testid=\"hero-image\" class=\"sc-814e9212-1 fcEyBx\"><img decoding=\"async\" sizes=\"(min-width: 1280px) 50vw, (min-width: 1008px) 66vw, 96vw\" srcset=\"https:\/\/ichef.bbci.co.uk\/news\/240\/cpsprodpb\/ae37\/live\/03ddbe10-6126-11ef-af52-71029fe3b80e.jpg.webp 240w,https:\/\/ichef.bbci.co.uk\/news\/320\/cpsprodpb\/ae37\/live\/03ddbe10-6126-11ef-af52-71029fe3b80e.jpg.webp 320w,https:\/\/ichef.bbci.co.uk\/news\/480\/cpsprodpb\/ae37\/live\/03ddbe10-6126-11ef-af52-71029fe3b80e.jpg.webp 480w,https:\/\/ichef.bbci.co.uk\/news\/640\/cpsprodpb\/ae37\/live\/03ddbe10-6126-11ef-af52-71029fe3b80e.jpg.webp 640w,https:\/\/ichef.bbci.co.uk\/news\/800\/cpsprodpb\/ae37\/live\/03ddbe10-6126-11ef-af52-71029fe3b80e.jpg.webp 800w,https:\/\/ichef.bbci.co.uk\/news\/1024\/cpsprodpb\/ae37\/live\/03ddbe10-6126-11ef-af52-71029fe3b80e.jpg.webp 1024w,https:\/\/ichef.bbci.co.uk\/news\/1536\/cpsprodpb\/ae37\/live\/03ddbe10-6126-11ef-af52-71029fe3b80e.jpg.webp 1536w\" src=\"https:\/\/ichef.bbci.co.uk\/news\/480\/cpsprodpb\/ae37\/live\/03ddbe10-6126-11ef-af52-71029fe3b80e.jpg.webp\" loading=\"eager\" alt=\"PA Media Janusz Racz, 67, is the first participant in trialling the BNT116 vaccine, made by German biotechnology company BioNTech.\" class=\"sc-814e9212-0 hIXOPW\"\/><span class=\"sc-814e9212-2 jesyMJ\">PA Media<\/span><\/div>\n<\/div>\n<p><figcaption class=\"sc-8353772e-0 cvNhQw\">Janusz Racz, 67, says he is &#8220;open to trying new things&#8221;<!-- --><\/figcaption><\/p>\n<\/figure>\n<div data-component=\"text-block\" class=\"sc-18fde0d6-0 dlWCEZ\">\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">A 67-year-old man has become the first person in the UK to try what doctors hope will be a revolutionary new treatment for lung cancer &#8211; a vaccine that tells the body how to fight and kill the disease. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">It uses the same mRNA technology as some Covid jabs to give instructions to the immune system.  <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">The early-stage trial  in which Janusz Racz is taking part will check the shot is safe. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">Some 34 research sites in seven countries, including University College London Hospitals NHS Foundation Trust in the UK, will recruit 130 patients to try it.<!-- --><\/p>\n<\/div>\n<p><h2 class=\"sc-518485e5-0 kRvAla\">Highly targeted<!-- --><\/h2>\n<\/p>\n<div data-component=\"text-block\" class=\"sc-18fde0d6-0 dlWCEZ\">\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">The treatment should specifically target cancer cells for destruction rather than healthy ones, hopefully meaning fewer side effects. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">It contains information about several markers found on the surface of lung cancer cells to teach the patient&#8217;s immune system what to find and fight. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">The BNT116 vaccine, made by German biotechnology company BioNTech, could be a game-changer, say experts. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">Prof Siow Ming Lee, who is clinical lead for the UK part of the trial, told the BBC&#8217;s Today programme: &#8220;We hope to kick-start this new era of mRNA cancer vaccine treatment for lung cancer.<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">&#8220;Hopefully, in combination with the current standard treatment &#8211; immunotherapy and chemotherapy &#8211; we can provide an additional immune boost.&#8221;<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">Mr Racz, from London, says he is open to trying new things. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">&#8220;I hope it will provide a defence against cancer cells. But I also thought that my participation in this research could help other people in future, and help this therapy become more widely available.<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">&#8220;As a scientist myself, I know that science can only advance if people agree to participate in programmes like this.&#8221;<!-- --><\/p>\n<\/div>\n<div data-component=\"text-block\" class=\"sc-18fde0d6-0 dlWCEZ\">\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">Mr Racz, who works in artificial intelligence, was diagnosed with lung cancer after having some breathing problems that he thought might be asthma. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">A medical scan (for an unrelated issue) revealed a tumour on his right lung.<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">NHS England national cancer director Dame Cally Palmer said shots like this one could be &#8220;revolutionary&#8221; in vaccinating people against their own cancers to prevent the disease returning.<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">&#8220;A cancer diagnosis is very worrying, but access to groundbreaking trials \u2013 alongside other innovations to diagnose and treat cancers earlier \u2013 provides hope. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">&#8220;We expect to see thousands more patients taking part in trials over the next few years,&#8221; she said.<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">The trial will recruit people with non-small cell lung cancer (NSCLC) from early-stage before surgery or radiotherapy, to late-stage disease or recurrent cancer &#8211; to have the jab alongside standard immunotherapy.<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">The other UK hospitals taking part include:<!-- --><\/p>\n<ul class=\"sc-5c9c90b0-0 cnfHHs\">\n<li class=\"sc-8d73edac-0 ezcCTE\">Cambridge University Hospitals NHS Foundation Trust<!-- --><\/li>\n<li class=\"sc-8d73edac-0 ezcCTE\">Velindre University NHS Trust<!-- --><\/li>\n<li class=\"sc-8d73edac-0 ezcCTE\">The Clatterbridge Cancer Centre NHS Foundation Trust<!-- --><\/li>\n<li class=\"sc-8d73edac-0 ezcCTE\">Guy\u2019s and St Thomas\u2019 NHS Foundation Trust<!-- --><\/li>\n<li class=\"sc-8d73edac-0 ezcCTE\">The Newcastle Upon Tyne Hospitals NHS Foundation Trust<!-- --><\/li>\n<\/ul>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">There are several other vaccines being used against different types of cancer.<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">Unlike vaccines to protect us from infectious diseases, such as measles, cancer treatment vaccines are for people who already have the illness. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">Cancer vaccines help your body\u2019s immune system recognise and attack cancer cells.<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">Some, like this latest one, are designed based on common markers that tend to occur only on cancer cells. Others are <!-- --><a target=\"_self\" href=\"https:\/\/www.bbc.co.uk\/news\/articles\/cl77qvd2krgo\" class=\"sc-c9299ecf-0 bZUiKB\" rel=\"noopener\">bespoke or tailor-made<!-- --><\/a> for an individual&#8217;s specific tumour. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">Cancer Research UK\u2019s chief executive, Michelle Mitchell, said: &#8220;We\u2019re pleased to see that another cancer vaccine trial has opened in the UK, allowing more patients to access cutting-edge therapies. <!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">&#8220;The science that helped us out of the worst of the Covid-19 pandemic continues to show promise as a potential treatment option for patients<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">&#8220;While very early stage, we look forward to seeing how the study progresses.&#8221;<!-- --><\/p>\n<\/div>\n<p><h2 class=\"sc-518485e5-0 kRvAla\">Lung cancer: Signs and symptoms<!-- --><\/h2>\n<\/p>\n<div data-component=\"text-block\" class=\"sc-18fde0d6-0 dlWCEZ\">\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">Lung cancer remains the leading cause of cancer deaths worldwide, with an estimated 1.8 million in 2020. Non-small cell lung cancer is the most common type.<!-- --><\/p>\n<p class=\"sc-eb7bd5f6-0 fYAfXe\">There are usually no signs or symptoms in the early stages, but things to see a doctor about include: <!-- --><\/p>\n<ul class=\"sc-5c9c90b0-0 cnfHHs\">\n<li class=\"sc-8d73edac-0 ezcCTE\">a cough that does not go away after a few weeks<!-- --><\/li>\n<li class=\"sc-8d73edac-0 ezcCTE\">a long-standing cough that gets worse<!-- --><\/li>\n<li class=\"sc-8d73edac-0 ezcCTE\">chest infections that keep coming back<!-- --><\/li>\n<li class=\"sc-8d73edac-0 ezcCTE\">coughing up blood<!-- --><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.bbc.com\/news\/articles\/ce806ndv8neo\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PA Media Janusz Racz, 67, says he is &#8220;open to trying new things&#8221; A 67-year-old man has become the first person in the UK to try what doctors hope will be a revolutionary new treatment for lung cancer &#8211; a vaccine that tells the body how to fight and kill the disease. It uses the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[64],"tags":[896,4683,4682,1316,591,514],"class_list":["post-8884","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-cancer","tag-lung","tag-promising","tag-starts","tag-trial","tag-vaccine"],"_links":{"self":[{"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/posts\/8884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/comments?post=8884"}],"version-history":[{"count":1,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/posts\/8884\/revisions"}],"predecessor-version":[{"id":8886,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/posts\/8884\/revisions\/8886"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/media\/8885"}],"wp:attachment":[{"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/media?parent=8884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/categories?post=8884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.godj.com\/news\/wp-json\/wp\/v2\/tags?post=8884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}